Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Gastritis D005756 27 associated lipids
Fibrosis D005355 23 associated lipids
Fever D005334 35 associated lipids
Fetal Growth Retardation D005317 9 associated lipids
Extravasation of Diagnostic and Therapeutic Materials D005119 3 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Epilepsy D004827 35 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Encephalitis D004660 15 associated lipids
Edema D004487 152 associated lipids
Ear Diseases D004427 7 associated lipids
Dyslexia D004410 3 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Disseminated Intravascular Coagulation D004211 7 associated lipids
Dictyocaulus Infections D004022 1 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Death, Sudden D003645 12 associated lipids
Cystitis D003556 23 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Coronary Thrombosis D003328 7 associated lipids
Coronary Disease D003327 70 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Contracture D003286 3 associated lipids
Constriction, Pathologic D003251 8 associated lipids
Conjunctivitis D003231 7 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Colonic Diseases D003108 5 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Colitis D003092 69 associated lipids
Cluster Headache D003027 4 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Cholestasis, Intrahepatic D002780 4 associated lipids
Cholestasis D002779 23 associated lipids
Cholecystitis D002764 8 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Brain Ischemia D002545 89 associated lipids
Central Nervous System Diseases D002493 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carbon Monoxide Poisoning D002249 9 associated lipids
Burns, Inhalation D002059 4 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Madi S et al. Allergen-induced bronchospasm in passively sensitized guinea pigs: influence of new substances in comparison to reference compounds. 1991 Agents Actions pmid:2058463
Braquet P and Esanu A New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists. 1991 Agents Actions pmid:2058466
Desai S and Barton R Role of platelet activating factor in the pathogenesis of active and passive models of experimental allergic encephalomyelitis in the rat. 1990 Agents Actions pmid:2285021
Howat DW et al. An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats. 1989 Agents Actions pmid:2801340
Appleby P and Bowen JG Cutaneous inflammatory disorders. 1990 Agents Actions pmid:2117335
Lundgren JD et al. Platelet activating factor and tracheobronchial respiratory glycoconjugate release in feline and human explants: involvement of the lipoxygenase pathway. 1990 Agents Actions pmid:2117336
Doyle SA et al. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid. 1990 Agents Actions pmid:2178317
Swingle KF and Reiter MJ Inhibition of Paf-acether-induced edema of the rat's paw. 1986 Agents Actions pmid:2875631
Flower RJ Background and discovery of lipocortins. 1986 Agents Actions pmid:2938452
Adnot S et al. Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets. 1987 Agents Actions pmid:3115070
Montrucchio G et al. The pattern of cardiovascular alterations induced by infusion of platelet-activating factor in rabbit is modified by pretreatment with H1-H2 receptor antagonists but not by cyclooxygenase inhibition. 1987 Agents Actions pmid:3115072
Morley J Platelet activating factor and asthma. 1986 Agents Actions pmid:3099555
Cahill M et al. Effect of des arginine9-bradykinin and other bradykinin fragments on the synthesis of prostacyclin and the binding of bradykinin by vascular cells in culture. 1988 Agents Actions pmid:3051930
Cunha FQ et al. Failure of PAF-acether to induce in vivo neutrophil migration. 1988 Agents Actions pmid:3055873
Touvay C et al. Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. 1986 Agents Actions pmid:3754380
Kusner EJ et al. Pharmacologic analysis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced increases in cutaneous vascular permeability in the rat. 1987 Agents Actions pmid:3577957
Pirotzky E et al. Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. 1985 Agents Actions pmid:4003192
Page CP et al. Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. 1985 Agents Actions pmid:4003195
Page CP et al. Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. 1985 Agents Actions pmid:4003196
Spicer BA et al. An investigation of the involvement of platelet activating factor in the non-histamine immediate hypersensitivity reaction in the rat peritoneal cavity. 1985 Agents Actions pmid:4003197
Boughton-Smith NK et al. Actions of nitric oxide on the acute gastrointestinal damage induced by PAF in the rat. 1992 Agents Actions pmid:1279960
Northover AM In vitro effects of PAF on venous endothelial cell actin disposition. 1992 Agents Actions pmid:1509977
Benveniste J Platelet-activating factor (PAF-acether): present status. 1981 Agents Actions pmid:6176101
Northover AM and Northover BJ Lectin-induced increase in microvascular permeability to colloidal carbon in vitro may involve protein kinase C activation. 1994 Agents Actions pmid:7942320
Tubaro E et al. In vitro and in vivo impact of a new glycosphingolipid on neutrophils. 1994 Agents Actions pmid:7879694
Canale P et al. TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. 1994 Agents Actions pmid:7879698
Meats JE et al. Identification of phospholipase D (PLD) activity in mouse peritoneal macrophages. 1993 Agents Actions pmid:8273553
Thomas TK et al. Differential antagonism of platelet activating factor-induced neutrophilia and gastric hemorrhage in the rat. 1993 Agents Actions pmid:8273566
Glaser KB et al. Pharmacological characterization of WAY-121,520: a potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2). 1993 Agents Actions pmid:8273577
Perret BA et al. Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes. 1981 Agents Actions pmid:6803540
Denburg JA et al. Platelet activating factor: regulation by mast cells and aspirin. 1984 Agents Actions pmid:6711391
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Benveniste J et al. Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types. 1982 Agents Actions pmid:7164945
Arnoux B et al. Release of PAF-acether from human blood monocytes. 1982 Agents Actions pmid:7164946
Fouque F et al. Platelet-activating factor (PAF-acether): thromboxane-independent synergism with adrenaline on human platelets and recent insights into its mode of action. 1982 Agents Actions pmid:7164947
Lefort J et al. Pharmacological properties of PAF-acether in the guinea-pig: platelet-dependent and independent reactions. 1982 Agents Actions pmid:7164948
Bonnet J et al. Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes. 1981 Agents Actions pmid:7340441
Denjean A et al. Bronchoconstriction induced by intratracheal administration of platelet-activating factor (PAF-acether) in baboons. 1981 Agents Actions pmid:7340444
Heller R et al. S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. 1993 Agents Actions pmid:7517616
Louis R et al. Potentiation of histamine release from human leucocytes by PAF. 1994 Agents Actions pmid:7521570
Izzo AA et al. Platelet activating factor potentiates rat paw oedema induced by different phlogogen agents. 1994 Agents Actions pmid:7524288
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Czarnetzki BM and Benveniste J Effect of synthetic PAF-acether on human neutrophil function. 1981 Agents Actions pmid:7041568
Camussi G et al. Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). 1981 Agents Actions pmid:7041569
de Bernardis E et al. Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema. 1994 Agents Actions pmid:7847181
Kelefiotis D and Vakirtzi-Lemonias C In vivo responses of mouse blood cells to platelet-activating factor (PAF): role of the mediators of anaphylaxis. 1993 Agents Actions pmid:8023738
Northover AM and Northover BJ Involvement of protein kinase C in the control of microvascular permeability to colloidal carbon. 1993 Agents Actions pmid:8304240
Morley J et al. Pharmacological evaluation of prophylactic anti-asthma drugs by reference to the pathological sequelae of exposure to allergen or platelet activating factor. 1988 Agents Actions Suppl. pmid:3262989
Subissi A and Criscuoli M Effects of LG 30435 on different platelet activating factor-induced responses. 1988 Agents Actions Suppl. pmid:3262990
Heuer H and Casals-Stenzel J Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge. 1988 Agents Actions Suppl. pmid:3262991